Cristina Hernando
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysis.
Journal: Cancer treatment reviews
Published: October 05, 2025
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 11, 2025
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 11, 2025
Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer.
Journal: Molecular medicine (Cambridge, Mass.)
Published: January 13, 2025
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 27, 2024
Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women.
Journal: Cancer communications (London, England)
Published: September 03, 2024
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.
Journal: Cell death discovery
Published: April 09, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 22, 2024
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
Journal: Journal of mammary gland biology and neoplasia
Published: October 27, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Journal: Cancers
Published: July 20, 2023
Last Updated: 09/26/2026